

Unstained
GAHu-Alexa 647
Ab #12
Ab #11
Ab #10
Ab #9
Ab #8
Ab #7
Ab #6
Ab #5
Ab #4
Ab #3
Ab #2
Ab #1
Antibody Clone
0
10
20
30
40
50
60
70
80
90
Mean Fluorescence Intensity

Fig. 1A



Mean Fluorescence Intensity
90
80
70
60
50
40
30
20
10
0
Ab#14
Ab#15
Ab#16
Ab#17
Ab#18
Ab#19
Ab#20
Ab#21
Ab#22
Ab#23
Ab#24
Ab#25
Ab#26
Ab#6
Antibody Clone

Fig. 1B

Binding of Antibodies to ErbB3 as Measured by SPR

$$K_D = k_d / k_a$$




Fig. 2A




Fig. 2B

Cell Binding Assay for Antibodies to MALME-3M cells

$$Y=Bmax*X/K_D+X$$




Fig. 2C




Fig. 2D



AB #6 IgG2 binding is specific to ErbB3.
RLU
200000
180000
160000
140000
120000
100000
80000
60000
40000
20000
0
0
200
400
600
800
1000
1200
Ab #6 [nM]
EGFR
BSA
ErbB3
TGFa

Fig. 3

Antibody#6 causes a decrease in total ErbB3 levels in MALME 3M melanoma cells *in vitro* measured by ELISA




Fig. 4



Downregulation of ErbB3 receptors on MALME-3M (melanoma) cells with Ab #6 IgG1 and IgG2 measured by FACS
Ab #6 IgG1
Counts
FL4-Height
Control
20nM_Ab #6_IgG2
Secondary Ab
20nM_Ab #6_IgG2

Fig. 5A



Downregulation of ErbB3 receptors on MALME-3M (melanoma) cells with Ab #6 IgG1 and IgG2 measured by FACS
Ab #6 IgG2
Counts
FL4-Height
Control
20nM_Ab #6_IgG2
Secondary Ab
20nM_Ab #6_IgG2

Fig. 5B



Timecourse of Ab #6
mediated ErbB3 downregulation
Cell surface ErbB3: 75%
Counts
100
80
60
40
20
0
10^0
10^1
10^2
10^3
10^4
Fl1-Height
0 hrs
Control
+100 nM Ab #6 IgG1-Alexa 488 (Unquenched)
+100 nM Ab #6 IgG1-Alexa 488 +
25 µg/ml anti-Alexa 488 (Quenched)

Fig. 6A



Timecourse of Ab #6
mediated ErbB3 downregulation
Cell surface ErbB3: 38%
Counts
100
80
60
40
20
0
10^0
10^1
10^2
10^3
10^4
Fl1-Height
0.5 hrs Post Treatment
Control
+100 nM Ab #6 IgG1-Alexa 488 (Unquenched)
+100 nM Ab #6 IgG1-Alexa 488 +
25 µg/ml anti-Alexa 488 (Quenched)

Fig. 6B



Timecourse of Ab #6
mediated ErbB3 downregulation
Cell surface ErbB3: 18%
Counts
FL1-Height
2 hr
Control
+100 nM Ab #6 IgG1-Alexa 488 (Unquenched)
+100 nM Ab #6 IgG1-Alexa 488 +
25 µg/ml anti-Alexa 488 (Quenched)

Fig. 6C



Timecourse of Ab #6
mediated ErbB3 downregulation
Cell surface ErbB3: 5%
Counts
FL1-Height
24 hr
Control
+100 nM Ab #6 IgG1-Alexa 488 (Unquenched)
+100 nM Ab #6 IgG1-Alexa 488 +
25 µg/ml anti-Alexa 488 (Quenched)

Fig. 6D



Ab #6 causes ErbB3 downregulation in melanoma cells in vivo
Total ErbB3 Levels in MALME3M PD Study 24hrs Post Injection
ngErbB3/mg total protein
80
70
60
50
40
30
20
10
0
Ab #1 IgG1
Ab #1 IgG2
Ab #11 IgG2
Ab #13 IgG1
Ab #13 IgG2
Ab #6 IgG1
Ab #6 IgG2
PBS control
Antibody Clone

Fig. 7



Total ErbB3 levels in ADRr xenografts
Total ErbB3 ng/mg total protein
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
PBS Control
Ab #6 treated
Antibody Treatment

Fig. 8



Ab #6 inhibits proliferation in MALME 3M melanoma cells measured by Cell Titer Glow assay
Control: 0% serum with no Antibody
Ab #6
ATP [M]
3.5×10 -6
2.5×10 -6
1.5×10 -6
-12
-11
-10
-9
-8
-7
-6
-5
Ab #6 Log[M]

Fig. 9



Ab #6 inhibits cell proliferation in ADRr (ovarian) cell line
Control: 0% serum in absence of Ab #6
Ab #6
ATP [M]
2.6×10-6
2.5×10-6
2.4×10-6
2.3×10-6
2.2×10-6
2.1×10-6
2.0×10-6
1.9×10-6
1.8×10-6
1.7×10-6
1.6×10-6
1.5×10-6
1.4×10-6
1.3×10-6
-12
-11
-10
-9
-8
-7
-6
-5
Ab #6 Log[M]

Fig. 10



Ab #6 inhibits cell proliferation in ACHN cell line
Control - 0% serum; without Ab #6
Ab #6
ATP [M]
8.5×10-6
8.0×10-6
7.5×10-6
7.0×10-6
6.5×10-6
6.0×10-6
5.5×10-6
5.0×10-6
-12
-11
-10
-9
-8
-7
-6
-5
Ab #6 log[M]

Fig. 11



Ab #6 inhibits ErbB3 phosphorylation in ADRr xenografts in vivo
pErbB3 levels in ARDr xenografts
pErbB3 ng/mg total protein
0.12
0.1
0.08
0.06
0.04
0.02
0
PBS Control
Ab #6 treated
Antibody Treatment

Fig. 12

Ab #6 IgG2/BTC

IC50	8.37e-10 M
95% CI	5.32e-10 to 1.32e-9




Fig. 13A

Ab #6 IgG2/BTC	
IC50	2.488e-009
95% CI	1.051e-009 to 5.889e-009




Fig. 13B

Ab #6 IgG2/TGFa	
IC50	4.901e-009
95% CI	1.965e-009 to 1.222e-008




Fig. 13C




Fig. 14A




Fig. 14B




Fig. 15A




Fig. 15B



Blocking BTC Binding by Erbitux but not Ab #6
Counts
100
80
60
40
20
0
10^0
10^1
10^2
10^3
10^4
FL2-Height
Control ADRr
200nm BTC
BTC+Ab #6
BTC+Erbitux

Fig. 15C




Fig. 16A




Fig. 16B




Ab #6 Inhibition of Tumor Growth
ADRr (Ovarian Cancer)
PBS Control
Ab#6 30ug
Ab#6 300ug
Tumor Volume p/6 (L x W²) in mm³
Days post initiation
Ab #6 Serum Levels at the end of the study
ug/ml MM121 in serum
PBS
Ab#6 30ug
Ab#6 300ug
Ab #6 Dose
*P<0.05

Fig. 17A

Ab #6 Inhibition of Tumor Growth






Fig. 17B

*P<0.05



Ab #6 Inhibition of Tumor Growth
OvCAR8 (Ovarian Cancer)
PBS Control
Ab#6 300ug
Ab#6 600ug
Ab#6 1500ug
Tumor Volume p/6 (L x W²) in mm³
Days post initiation
0 4 7 11 14 16 21 25 28 32 35 39 42 46 49 52 55 58 61
Ab #6 Serum Levels at the end of the study
ug/ml MM121 in serum
PBS
Ab#6 300ug
Ab#6 600ug
Ab#6 1500ug
Ab #6 Dose
*P<0.05

Fig. 17C



Ab #6 Inhibition of Tumor Growth
COLO357 (Pancreatic Cancer)
PBS Control
Ab#6 300ug
Ab#6 600ug
Ab#6 1500ug
Tumor Voume p/6 (L x W²) in mm³
Days Post Initiation
*P<0.05
Ab #6 Serum Levels at the end of the study
ug/ml NIM1121 in serum
PBS
Ab#6 300ug
Ab#6 600ug
Ab#6 1500ug
Ab #6 Dose

Fig. 17D




Fig. 18A




Fig. 18B




Fig. 19A




Fig. 19B




Fig. 20A




Fig. 20B

Ab # 6 VH amino acid sequence (SEQ ID NO:1)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYVMAWVRQAPGKGLEWVSSISSS
GGWTLYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGLKMATIFD
YWGQGTLVTVSS

Ab # 6 VL amino acid sequence (SEQ ID NO:2)
QSALTQPASVSGSPGQSITISCTGTSSDVGSYNVVSWYQQHPGKAPKLIIYEVSQR
PSGVSNRFSGSKSGNTASLTISGLQTEDEADYYCCSYAGSSIFVIFGGGTKVTVL

Ab # 3 VH amino acid sequence (SEQ ID NO:3)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSAYNMRWVRQAPGKGLEWVSVIYPS
GGATRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGYYYYGMDV
WGQGTLVTVSS

Ab # 3 VL amino acid sequence (SEQ ID NO:4)
QSVLTQPPSASGTPGQRVTISCSGSDSNIGRNYIYWYQQFPGTAPKLLIYRNNQRP
SGVPDRISGSKSGTSASLAISGLRSEDEAEYHCGTWDDSLSGPVFGGGTKLTVL

Ab # 14 VH amino acid sequence (SEQ ID NO:5)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSAYGMGWVRQAPGKGLEWVSYISPS
GGHTKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVLETGLLVD
AFDIWGQGTMVTVSS

Ab # 14 VL amino acid sequence (SEQ ID NO:6)
QYELTQPPSVSVYPGQTASITCSGDQLGSKFVSWYQQRPGQSPVLVMYKDKRRP
SEIPERFSGSNSGNTATLTISGTQAIDEADYYCQAWDSSTYVFGTGTKVTVL

Ab # 17 VH amino acid sequence (SEQ ID NO:35)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSWYGMGWVRQAPGKGLEWVSYISPS
GGITVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLNYYYGLDV
WGQGTTVTVSS

Ab # 17 VL amino acid sequence (SEQ ID NO:36)
QDIQMTQSPSSLSASVGDRITITCQASQDIGDSLNWYQQKPGKAPRLLIYDASNLE
TGVPPRFSGSGSGTDFTFTFRSLQPEDIATYFCQQSANAPFTFGPGTKVDIK

Ab # 19 VH amino acid sequence (SEQ ID NO:37)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYGMWWVRQAPGKGLEWVSYIGSS
GGPTYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGGRGTPYYFDS
WGQGTLVTVSS

Ab # 19 VL amino acid sequence (SEQ ID NO:38)
QYELTQPASVSGSPGQSITISCTGTSSDIGRWNIVSWYQQHPGKAPKLMIYDVSNRPSGVSNRF
SGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTWVFGGGTKLTVL

Fig. 21A

Ab # 6 VH CDR1 (SEQ ID NO:7)
HYVMA

Ab # 6 VH CDR2 (SEQ ID NO:8)
SISSSGGWTLYADSVKG

Ab # 6 VH CDR3 (SEQ ID NO:9)
GLKMATIFDY

Ab # 6 VL CDR1 (SEQ ID NO:10)
TGTSSDVGSYNVVS

Ab # 6 VL CDR2 (SEQ ID NO:11)
EVSQRPS

Ab # 6 VL CDR3 (SEQ ID NO:12)
CSYAGSSIFVI

Ab # 3 VH CDR1 (SEQ ID NO:13)
AYNMR

Ab # 3 VH CDR2 (SEQ ID NO:14)
VIYPSGGATRYADSVKG

Ab # 3 VH CDR3 (SEQ ID NO:15)
GYYYYGMDV

Ab # 3 VL CDR1 (SEQ ID NO:16)
SGSDSNIGRNYIY

Ab # 3 VL CDR2 (SEQ ID NO:17)
RNNQRPS

Ab # 3 VL CDR3 (SEQ ID NO:18)
GTWDDSLSGPV

Fig. 21B

Ab # 14 VH CDR1 (SEQ ID NO:19)
AYGMG

Ab # 14 VH CDR2 (SEQ ID NO:20)
YISPSGGHTKYADSVKG

Ab # 14 VH CDR3 (SEQ ID NO:21)
VLETGLLVDAFDI

Ab # 14 VL CDR1 (SEQ ID NO:22)
SGDQLGSKFVS

Ab # 14 VL CDR2 (SEQ ID NO:23)
YKDKRRPS

Ab # 14 VL CDR3 (SEQ ID NO:24)
QAWDSSTYV

Ab # 17 VH CDR1 (SEQ ID NO:39)
WYGMG

Ab # 17 VH CDR2 (SEQ ID NO:40)
YISPSGGITVYADSVKG

Ab # 17 VH CDR3 (SEQ ID NO:41)
LNYYYGLDV

Ab # 17 VL CDR1 (SEQ ID NO:42)
QASQDIGDSLN

Ab # 17 VL CDR2 (SEQ ID NO:43)
DASNLET

Ab # 17 VL CDR3 (SEQ ID NO:44)
QQSANAPFT

Ab # 19 VH CDR1 (SEQ ID NO:45)
RYGMW

Ab # 19 VH CDR2 (SEQ ID NO:46)
YIGSSGGPTYYVDSVKG

Ab # 19 VH CDR3 (SEQ ID NO:47)
GRGTPYYFDS

Ab # 19 VL CDR1 (SEQ ID NO:48
TGTSSDIGRWNIVS

Ab # 19 VL CDR2 (SEQ ID NO:49)
DVSNRPS

Ab # 19 VL CDR3 (SEQ ID NO:50)
SSYTSSSTWV

Fig. 21C

Ab # 6 VH Codon Optimized Nucleic Acid Sequence (SEQ ID NO:25)

gaggtgcagctgctggagagcggcggagggctggtccagccaggcggcagcctgaggctgtcctgcgccgccagcggcttcac
cttcagccactacgtgatggcctgggtgcggcaggccccaggcaagggcctggaatgggtgtccagcatcagcagcagcggcgg
ctggaccctgtacgccgacagcgtgaagggcaggttcaccatcagcagggacaacagcaagaacaccctgtacctgcagatgaac
agcctgagggccgaggacaccgccgtgtactactgcaccaggggcctgaagatggccaccatcttcgactactggggccagggc
accctggtgaccgtgagcagc

Ab # 6 VL Codon Optimized Nucleic Acid Sequence (SEQ ID NO:26)

cagtccgccctgacccagcccgccagcgtgagcggcagcccaggccagagcatcaccatcagctgcaccggcaccagcagcga
cgtgggcagctacaacgtggtgtcctggtatcagcagcaccccggcaaggcccccaagctgatcatctacgaggtgtcccagagg
cccagcggcgtgagcaacaggttcagcggcagcaagagcggcaacaccgccagcctgaccatcagcggcctgcagaccgagg
acgaggccgactactactgctgcagctacgccggcagcagcatcttcgtgatcttcggcggagggaccaaggtgaccgtccta

Ab # 3 VH Codon Optimized Nucleic Acid Sequence (SEQ ID NO:27)

gaggtgcagctgctggaaagcggcggagggctggtgcagccaggcggcagcctgaggctgtcctgcgccgccagcggcttcac
cttcagcgcctacaacatgagatgggtgcggcaggccccaggcaagggcctggaatgggtgtccgtgatctaccccagcggcgg
agccaccagatacgccgacagcgtgaagggcaggttcaccatcagcagggacaacagcaagaacaccctgtacctgcagatgaa
cagcctgagggccgaggacaccgccgtgtactactgcgccaggggctactactactacggcatggacgtgtggggccagggcac
cctggtgaccgtgagcagc

Ab # 3 VL Codon Optimized Nucleic Acid Sequence (SEQ ID NO:28)

cagagcgtgctgacccagcccccaagcgccagcggcaccccaggccagagggtgaccatcagctgcagcggcagcgacagca
acatcggcaggaactacatctactggtatcagcagttccccggcaccgcccccaagctgctgatctacaggaacaaccagaggccc
agcggcgtgcccgacaggatcagcggcagcaagagcggcaccagcgccagcctggccatcagcggcctgagaagcgaggac
gaggccgagtaccactgcggcacctgggacgacagcctgagcggcccagtgttcggcggagggaccaagctgaccgtccta

Fig. 22A

Ab # 14 VH Nucleic Acid Sequence (SEQ ID NO:29)

gaagttcaattgttagagtctggtggcggtcttgttcagcctggtggttctttacgtctttcttgcgctgcttccggattcactttctct
gcttacggtatgggttgggttcgccaagctcctggtaaaggtttggagtgggtttcttatatctctccttctggtggccatactaag
tatgctgactccgttaaaggtcgcttcactatctctagagacaactctaagaatactctctacttgcagatgaacagcttaagggc
tgaggacacggccgtatattactgtgcgaaagtactggaaactggcttattggttgatgcttttgatatctggggccaagggaca
atggtcaccgtctcaagc

Ab # 14 VL Nucleic Acid Sequence (SEQ ID NO:30)

cagtacgaattgactcagccaccctcagtgtccgtgtacccaggacagacagccagcatcacctgctctggagatcaattggg
gagtaaatttgtttcctggtatcagcagaggccaggccagtcccctgtgttggtcatgtataaagataaaaggcggccgtcaga
gatccctgagcgattctctggctccaactctgggaacacagccactctgaccatcagcgggacccaggctatagatgaggct
gactattattgtcaggcgtgggacagcagcacttatgtcttcggcactgggaccaaggtcaccgtccta

Ab # 6 VH Pre-Optimization Nucleic Acid Sequence (SEQ ID NO:31)

gaagttcaattgttagagtctggtggcggtcttgttcagcctggtggttctttacgtctttcttgcgctgcttccggattcactttctct
cattacgttatggcttgggttcgccaagctcctggtaaaggtttggagtgggtttcttctatctcttcttctggtggctggactctttat
gctgactccgttaaaggtcgcttcactatctctagagacaactctaagaatactctctacttgcagatgaacagcttaagggctg
aggacacagccgtgtattactgtactagaggtctcaagatggctacaatttttgactactggggccagggcaccctggtcaccg
tctcaagc

Ab # 6 VL Pre-Optimization Nucleic Acid Sequence (SEQ ID NO:32)

cagagcgctttgactcagcctgcctccgtgtctgggtctcctggacagtcgatcaccatctcctgcactggaaccagcagtgat
gttgggagttataatgttgtctcctggtaccaacaacacccaggcaaagcccccaaactcatcatttatgaggtcagtcagcgg
ccctcaggggtttctaatcgcttctctggctccaagtctggcaacacggcctccctgacaatctctgggctccagactgaggac
gaggctgattattactgctgctcatatgcaggtagtagtattttcgtgatattcggcggagggaccaaggtgaccgtccta

Ab # 3 VH Pre-Optimization Nucleic Acid Sequence (SEQ ID NO:33)

gaagttcaattgttagagtctggtggcggtcttgttcagcctggtggttctttacgtctttcttgcgctgcttccggattcactttctct
gcttacaatatgcgttgggttcgccaagctcctggtaaaggtttggagtgggtttctgttatctatccttctggtggcgctactcgtt
atgctgactccgttaaaggtcgcttcactatctctagagacaactctaagaatactctctacttgcagatgaacagcttaagggct
gaggacacggccgtgtattactgtgcgagagggtactactactacggtatggacgtctggggccaaggcaccctggtcaccg
tctcaagc

Ab # 3 VL Pre-Optimization Nucleic Acid Sequence (SEQ ID NO:34)

cagagcgtcttgactcagccaccctcagcgtctgggacccccgggcagagggtcaccatctcgtgttctggaagcgactcca
acatcggaagaaattatatatattggtaccagcaattcccaggaacggcccccaagctcctcatctataggaataatcagcggc
cctcaggggtccctgaccgaatctctggctccaagtctggcacctcagcctccctggccatcagtgggctccggtccgaggat
gaggctgagtatcactgtggaacatgggatgacagcctgagtggtccggtattcggcggagggactaagctgaccgtccta

Fig. 22B

- **Ab #6 VLb**:
- QSALTQPASVSGSPGQSITISCTGTSSDVGSYNVVSWYQQHPGKAPK LMIYEVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYA GSSIFVIFGGGTKVTVL (SEQ ID NO:51)

- **Ab #17 VK1b:**
- QDIQMTQSPSSLSASVGDRITITCQASQDIGDSLNWYQQKPGKAPRLL IYDASNLETGVPPRFSGSGSGTDFTFTFRSLQPEDIATYFCQQSANAP FTFGPGTKVDIR (SEQ ID NO:52)

- **Ab #19 VL2b:**
- QYELTQPASVSGSPGQSITISCTGTSSDIGRWNIVSWYQQHPGKAPK LMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTS SSTVVFGGGTKLTVL (SEQ ID NO:53)

Fig. 23



Cell Line
MCF-7
T47D
Colo-357
VEGF FU
8000
7000
6000
5000
4000
3000
2000
1000
0
None(0%FBS-medium)
10nM HRG ECD
HRG+2u Ab#6
HRG+4uM Ab #6
HRG+8uM Ab #6
None(0%FBS-medium)
10nM HRG ECD
HRG+2uM Ab #6
HRG+4uM Ab #6
HRG+8uM Ab #6
None(0%FBS-medium)
10nM HRG ECD
HRG+2uM Ab #6
HRG+4uM Ab #6
HRG+8uM Ab #6
Treatment

Fig. 24A



Cell Line
OVCAR8
COLO357
H1975
pg/ug VEGF
10.0
8.0
6.0
4.0
2.0
0.0
20.0
16.0
12.0
Control
Ab #6
Treatment

Fig. 24B




Correlation of phosphoErbB3 inhibition and inhibition of VEGF Secretion
Cell Line
COLO357
H1975
OvCAR8
% Inhibition of VEGF
90
80
70
60
50
40
30
20
10
0
40
50
60
70
% Inhibition of pErbB3

Fig. 24C



RPMI media alone
RPMI + 8uM Ab #6
RPMI + 10% FBS
10% FBS + 8uM Ab #6

Fig. 25




Fig. 26A




Fig. 26B




Fig. 26C




Fig. 27A




Fig. 27B




Fig. 28




Fig. 29A





Fig. 29B

Fig. 30


100
80
60
40
20
0
% of Max
10^0
10^1
10^2
10^3
FL4-H:: GAH-647
Sample Name
ErbB3_trunc_Ab#6+GAH-647
ErbB3_trunc_GAH-647only.046